A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER

A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER

IntroductionJUNIPER compared the efficacy and safety of abemaciclib, a selective cyclin-dependent kinase 4 and 6 inhibitor, with erlotinib in patients with non-small cell lung cancer (NSCLC) harboring a Kirsten rat sarcoma (KRAS) mutation.MethodsJUNIPER was a Phase III, multicenter, randomized, open...

Full description

Bibliographic Details
Main Authors: Jonathan W. Goldman, Julien Mazieres, Fabrice Barlesi, Konstantin H. Dragnev, Marianna Koczywas, Tuncay Göskel, Alexis B. Cortot, Nicolas Girard, Claas Wesseler, Helge Bischoff, Ernest Nadal, Keunchil Park, Shun Lu, Alvaro Taus, Manuel Cobo, Shawn T. Estrem, Sameera R. Wijayawardana, Kellie Turner, Gerard Joseph Oakley, Karla C. Hurt, Alan Y. Chiang, Anwar M. Hossain, William J. John, Luis Paz-Ares
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-10-01
Series:Frontiers in Oncology
Subjects:
platinum-resistant
erloitinib
abemaciclib
KRAS
NSCLC
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2020.578756/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2020.578756/full

Similar Items